Table 2.

Breakdown of patients on chemotherapy in relation to the disease subtype

ATL subtype (n = 14)	n (%)	Therapy
		mLSG15/-L n (%)	CHOP/-La n (%)
Acute	10 (71)	6 (43)	4 (29)
Lymphoma	1 (7)	1 (7)	0 (0)
Chronic	3 (21)	2 (14)	1 (7)

PTCL subtype (n = 11)	n (%)	Therapy
		CHOP n (%)	CHOP-La n (%)
AITL	5 (45)	1 (9)	4 (36)
PTCL-NOS	3 (27)	1 (9)	2 (18)
ALCL ALK-	1 (9)	1 (9)	0 (0)
EATL	1 (9)	0 (0)	1 (9)
SPTCL	1 (9)	0 (0)	1 (9)

AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large cell lymphoma, ALK anaplastic lymphoma kinase, ATL adult T-cell leukemia–lymphoma, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOP-L CHOP-like regimen, CHOP/-L CHOP or CHOP-like regimen, EATL enteropathy-associated T-cell lymphoma, mLSG15 vincristine, cyclophosphamide, doxorubicin, prednisone and doxorubicin, ranimustine, prednisone and vindesine, etoposide, carboplatin, prednisone, mLSG15/-L mLSG15 or mLSG15-like regimen, NOS not otherwise specified, PTCL peripheral T-cell lymphoma, SPTCL subcutaneous panniculitis-like T-cell lymphoma

^aTHP-COP, vincristine, pirarubicin, cyclophosphamide, and prednisone